InvestSMART

Control Bionics Limited (ASX:CBL)

ALERT: Price-sensitive ASX Announcement for CBL
Current share price for CBL : $0.059 -0.007 (-10.61%)+
Announcement
Release
31 Jul 2026 8:31AM
Price at Release
$0.066
Full Release
download
Summary
Control Bionics Limited reported a strong quarter ending 30 June 2026, highlighted by the completion of Tranche 1 of a A$9.8 million capital raising and the appointment of Professor Nicholas Opie to the Board. The company noted increasing US wholesale revenue and anticipated further growth in its European markets, particularly with a forthcoming German distribution agreement. Net cash outflows for the quarter were $1.6 million, impacted by NDIS approval delays and a transition in the North American market. The company secured a $400,000 loan facility against its R&D tax refund and projected cash availability for 1.3 quarters. The completion of Tranche 2 of its capital raise is subject to shareholder approval.
Key Points
  • Control Bionics completed Tranche 1 of a A$9.8 million capital raising.
  • Professor Nicholas Opie joined the Board as a Non-Executive Director.
  • US wholesale revenue increased with further expansion expected.
  • NextLevel iOS device program is on track for Q1FY27 launch.
  • European expansion with a German distribution agreement expected.
  • Net cash outflows were $1.6 million with continued NDIS approval delays.
  • Company secured a $400,000 loan facility against anticipated R&D tax refund.
  • Tranche 2 of capital raising subject to shareholder approval.
  • Estimated cash available for operations is 1.3 quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.